*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
A well-known Eastern medicine supplement may help avoid the most common cause of liver transplantation, according to a study by researchers at the Stanford University School of Medicine. The finding came as a surprise to the scientists, who used a number of advanced genetic and genomic techniques in mice to identify a molecular pathway that counters acetaminophen toxicity, which leads to liver failure. The scientists published their work online November 18 in Genome Research.
During this week's podcast Dr. Gary Peltz talks about the significance and impact of acetaminophen-related liver damage. He describes the experiment that his team carried out, focusing on the specific genetic and genomic methods that were employed and the results that were obtained.
Dr. Peltz also discusses the role of S-methylmethionine in mitigating or preventing acetaminophen-related liver damage and the importance of the enzyme Bhmt2 in metabolizing acetaminophen's harmful byproducts. He explains how the results of the study reported in Genome Research might ultimately lead to a new way to treat acetaminophen-related liver damage.
Gary Peltz, M.D., Ph.D. is a Professor in the Anesthesia Department at
Stanford University School of Medicine.. He received his M.D. and Ph.D. degrees from
Stanford; and did his medical residency and rheumatology fellowship at
UCSF. He is also certified as a specialist in internal medicine and a
sub-specialist in rheumatology. His research uses integrative genomic
analysis methods to identify the genetic basis for disease
susceptibility and drug response. He is the author of 78 papers; and
developed a computational method for mouse genetic analysis that was
used to discover novel and patented treatments for asthma,
osteoporosis (n=2), and narcotic drug addiction. He has 18 years of
experience within large pharmaceutical companies, and was Head of
Genetics and Genomics at Roche Palo Alto for 7 years.